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Abstract 
Background: Metastasis still remains the major cause of therapeutic failure, poor 
prognosis and high mortality in epithelial ovarian cancer (EOC) patients. Previously, 
we showed that EOC cells secrete a range of factors with potential pro-angiogenic 
activity, in disease-relevant human microvascular omental endothelial cells 
(HOMECs), including the lysosomal protease cathepsin L (CathL). Thus, the aim of 
this study was to examine potential pro-proliferative and pro-migratory effects of CathL 
in HOMECs and the activated signalling pathways, and whether these proangiogenic 
responses are dependent on CathL-catalytic activity. 
Methods: HOMECs proliferation was investigated using WST-1, BrdU and CyQUANT 
assays. Cell migration was examined using a Cultrex Cell 96 transwell migration 
assay. A range of pHs were assayed to assess enzyme activity in the presence of 
CathL-specific fluorogenic substrate FY-CHO. Activation of cell signalling pathways 
was tested using commercially available phosphokinase array and intact cell-based 
ELISAs. 
Results: We show for the first time that CathL has a potent pro-proliferative and pro-
migratory effect on HOMECs. For instance, CathL significantly increases HOMEC 
proliferation (134.8±14.7% vs control 100%) and migration (146.6±17.3% vs control 
100%). Our data strongly suggests that these proangiogenic effects of CathL are 
mediated via a non-proteolytic manner. Finally, we show that CathL-induced activation 
of the ERK1/2 pathway is involved in inducing these cellular effects in HOMECs.  
Conclusion: These data suggest that CathL acts as an extracellular ligand and plays 
an important pro-angiogenic, and thus pro-metastatic, role during EOC metastasis to 
the omentum, by activating the omental microvasculature, and thus can potentially be 
targeted therapeutically in the future. 
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1. Introduction 
Epithelial ovarian cancer (EOC), is the seventh most common cancer in women, and 
has a poor prognosis due to a lack of defined symptoms and therefore, early detection. 
Approximately 200,000 women suffer from the disease worldwide, with an estimated 
125,000 deaths annually. Pathologically, ovarian tumours frequently spread initially to 
the omentum, facilitating further spread and leading to advanced disease with 
widespread metastasis at diagnosis. This presents a considerable therapeutic 
challenge, and as a result, overall survival ranges from 30 to 50%.  
 
The predominant mechanism  of EOC metastasis  to the omentum is via the 
transcoelomic route within the peritoneum [1]. Ovarian tumour cells attach to the 
mesothelium of the omentum, invade the local tissue and then initiate angiogenesis to 
sustain secondary tumour growth. Tumour-induced angiogenesis, i.e. growth of new 
blood vessels from existing ones, requires a complex interplay between tumour and 
resident cells, with secretion of growth factors and chemokines that ultimately leads to 
activation of a pro-angiogenic phenotype in the host omental microvascular endothelial 
cells (ECs) and subsequently neovascularisation [2-6].  
Conventionally, vascular endothelial growth factor A (VEGFA) has been known to be 
a major pro-angiogenic target in anti-angiogenic therapies in cancer [7, 8].  However, 
our previous studies have indicated that alternative EOC-secreted pro-angiogenic 
factors are involved in inducing angiogenic changes in the omental ECs during 
metastasis of ovarian cancer [9].  These data are supported by the observation that 
anti-VEGFA therapy (bevacizumab) has shown limited efficacy in patients with ovarian 
cancer [10], highlighting the need for a clearer understanding of the pro-angiogenic 
pathways involved.  
One of the alternative proangiogenic factors we identified is cathepsin L (CathL), a 
cysteine endopeptidase, that physiologically plays an important role in degrading 
endocytosed proteins as well as intracellular proteins [11, 12]. Although CathL resides 
in lysosomes in its active form it has also been shown to be secreted from cancer cells 
by both ourselves (from EOC cells), as mentioned above [9] and others e.g. from a 
murine fibrosarcoma cell line KHT-LP1 [13], although the mechanism is unclear. 
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A possible role for secreted CathL in ovarian cancer development and metastasis has 
been reported in studies showing an increased level of secreted CathL in the sera of 
malignant EOC patients compared with patients with benign tumours and healthy 
controls [14]. Additionally, it has been shown to be involved in the invasion and 
metastasis of EOC through proteolytic degradation of the ECM, and hence was 
suggested to be a marker of advanced staged ovarian cancer [14]. This was supported 
by our previous work demonstrating that not only is CathL expressed in metastatic 
EOC cells in the omentum, but also that the endothelium of vessels within omentum 
hosting metastatic ovarian high-grade serous carcinoma expressed significantly 
increased CathL in vivo compared with omentum from control patients with benign 
ovarian cystadenoma [15]. 
 
Despite the emerging role for CathL in ovarian tumour development and angiogenesis, 
the exact involvement of extracellular CathL and the downstream cellular signalling 
pathways activated by the protein are still poorly understood and remain to be 
examined. The therapeutic challenge posed by EOC requires a fuller understanding 
of the process involved in secondary tumour formation within the omentum, in order 
to facilitate development of treatment strategies. We have previously published a 
technique for isolating disease relevant HOMECs [16] and here we use this cell model 
to (a) investigate whether CathL exerts its proliferative and/or migratory effects through 
a proteolytic or non-proteolytic mechanism and (b) activation of intracellular  signalling 
cascades upstream of these functional responses to CathL. We report for the first time 
that CathL significantly increases HOMEC proliferation and migration via proteolytic-
independent mechanisms. Additionally, we also demonstrate activation of intracellular 
kinases ERK1/2 and AKT(S473) as part of the signalling cascade in CathL-induced 
proliferation and migration in HOMECs. 
 
2. Method 
 
2.1. Primary cell culture 
Non-malignant omental tissue samples were collected from patients undergoing 
surgery at the Royal Devon and Exeter NHS Foundation Trust (Exeter, United 
5 
 
Kingdom) with ethical approval and informed written consent. HOMECs were isolated, 
characterised and cultured as primary cells as previously described [16, 17]. Briefly, 
HOMECs were cultured in endothelial cell (EC) growth media (MV2, PromoCell, 
Heidelberg, Germany) supplemented with supplied growth factors, 5% (v/v) foetal calf 
serum (FCS) and 0.1% (v/v) gentamycin (Sigma, Poole, UK). Cells were maintained 
at 37°C in a humidified atmosphere supplemented with 5 % CO2 [17].  
2.2. Cell proliferation assay 
2.2.1 WST-1 assay 
Investigation of HOMEC proliferation was as previously described [17]. Briefly, cells 
were seeded at a density of 1x104 cells per well in 2% (w/v) gelatin (Sigma, Poole, UK) 
coated 96-well plates (Greiner Bio One, Stonehouse, UK) and treated overnight in 
growth factor-deprived media containing 2% (v/v) FCS. After 24 hours, treatments 
(recombinant CathL (from human liver) 50ng/ml, VEGF165 (20ng/ml as positive control 
± inhibitors) were added at the given concentrations (Table 1) and incubated for 72 
hours. Subsequently, WST-1 reagent (Roche, Welwyn Garden City, UK) was added 
to the assay medium and absorbance was measured at 450 nm against the blank in 
a PHERAstar BMG plate-reader [17].  
2.2.2 BrdU assay 
Cells were seeded in 2% gelatin pre-coated 96 well plates at a density of 
20,000cells/well in starvation media containing 2% FCS. After overnight incubation, 
cells were treated with or without CathL (50 ng/ml) and incubated for 48 hours. A 
commercially available BrdU reagent (Merck Chemicals Ltd., Nottingham, UK) was 
added to the wells for the last 24 hour incubation and cellular proliferation was 
assessed (according to the manufacturer’s instructions) based on fluorescence 
intensity using a SpectraMax plate-reader (Molecular Devices, Berkshire, UK) at 
Ex/Em of 450/550 nm. 
2.2.3 CyQUANT assay 
This procedure was performed according the manufacturers instruction. Briefly, after 
72 hour treatment with CathL (50 ng/ml), media was removed from each well, followed 
by addition of the dye binding solution (1X HBSS buffer) containing CyQUANT NF dye 
reagent (Fisher Scientific, Loughborough, UK). After 2 hour incubation, the plates were 
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read at Ex/Em: 485/530 using a FLUOstar BMG plate-reader (BMG Labtech Ltd, 
Bucks, UK) and cell proliferation was assessed based on the fluorescence intensity 
against the background containing HBSS buffer. 
2.3. Examination of the dependence of exogenous CathL activity on pH  
The following experiments were carried out as previously described [17]. 
2.3.1. Measurement of pH of cell culture media during cell culture 
HOMECs were seeded at a density of 3x105 cells per well in 6 well plates, based on 
preliminary experiments. After overnight incubation in growth factor depleted media as 
above, fresh media supplemented ± CathL (50ng/ml) was added. The concentration 
of CathL was derived from cell proliferation experiments as discussed later. Culture 
media was collected, and pH was measured after 24, 48 and 72 hours using an ABL80 
FLEX blood-gas analyser (Radiometer, Crawley, UK). pH of medium-only was also 
measured at the beginning of incubation period. 
 
2.3.2 Measurement of enzymatic activity of CathL at different pHs 
CathL proteolytic activity was measured using a CathL-specific fluorogenic substrate 
Z-Val-Val-Arg-AMC, (ZVA, 5µmol/l, Enzo Life Sciences, Exeter, UK), in the presence 
or absence of the CathL inhibitor FY-CHO (10 µmol/l) in 96-well plates (Greiner Bio 
One, Stonehouse, UK). Prepared buffer solutions at specific pHs containing ZVA ± 
FY-CHO were added to the wells (100 µl). Subsequently, 20 µl of 300 ng/ml CathL 
was added as required to make up the final volume of 120 µl (50 ng/ml CathL). Control 
wells contained ZVA or ZVA plus FY-CHO, and 20 µl of corresponding pH buffer 
solution. The plate was shaken for 60 seconds in a plate-reader immediately prior to 
fluorescence reading at Ex/Em: 365/440. The experiment was performed away from 
direct light exposure. The pH buffer solutions were prepared by mixing citric acid 
monohydrate and Na2HPO4 solutions and 0.005% (v/v) Tween 20 (Sigma-Aldrich, 
Poole, UK) in the correct proportions to ensure a final pH of: 3, 3.6, 4, 4.6, 5, 5.6, 6, 
6.6, 7 and 7.6 (data not shown). 
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2.4. Detection of phosphorylation of intracellular signalling intermediates 
2.4.1. Phosphokinase array 
Upregulation of phosphorylation of intracellular kinases was detected using a 
Proteome Profiler Human Phospho-Kinase Array kit (Bio-Techne Ltd., Abingdon, UK), 
according to the manufacturer’s instructions, and as previously described [17]. Briefly, 
HOMECs were seeded in 10 cm2 petri dishes and cultured as above until confluent. 
Cells were starved overnight and then treated ± 50 ng/ml CathL, for 4 minutes and 
subsequently lysed. A BCA protein assay (Fisher Scientific, Loughborough, UK) was 
performed to quantify the total protein levels in each lysate. Controls received carrier 
alone. 200 µg of protein (lysate) was incubated with antibody coated membranes and 
levels of phosphorylated proteins were assessed by chemiluminescence detected on 
film. The relative expression of specific phosphorylated proteins was determined 
following quantification of spot density on scanned images by Image-J. The results are 
expressed as mean dot density (arbitrary units). 
 
2.4.2. Cell based ELISA 
Phosphorylation levels of ERK1/2 and AKT(S473) were measured using specific cell-
based ELISA kits (Bio-Techne Ltd., Abingdon, UK) according to the manufacturer’s 
instructions, and as previously described [17]. Cells were treated ± VEGF165 (20 ng/ml, 
positive control) and CathL (50 ng/ml) in the presence or absence of MEK1/2 
(upstream of ERK1/2) and AKT inhibitors at their given concentrations (Table 1) for 4 
and/or 10 minutes. Multiple time points were tested for the phosphorylative status of 
kinases as activation of intracellular kinases can be transient [18]. The shorter time 
point (4 minutes) for CathL was selected because previous reports suggest that 
MAPK/ERK1/2 and AKT phosphorylation are maximum at 4-5 minutes [19]. 
Fluorescence intensity was measured and the results are expressed as fold change 
in phospho-ERK1/2 or -AKT relative to total ERK or AKT levels (compared to control).  
 
2.5. HOMEC migration 
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Assessment of cellular migration was carried out using a Cultrex Cell 96 transwell 
migration assay (Bio-Techne Ltd., Abingdon, UK) as previously described [17]. Briefly, 
cells were incubated in growth factor-deprived media supplemented with 0.5% FCS 
overnight. Next, cells were seeded at a density of 5x104 in the upper assay chamber 
and treated ± VEGF165 (20ng/ml, positive control) and/or CathL (50ng/ml) and in the 
presence or absence of MEK1/2 and/or AKT(S473) inhibitors at their given 
concentrations (Table 1). Negative controls received carrier alone. After 6 hours 
incubation at 37oC, the bottom chambers were washed, followed by addition of cell 
dissociation solution/calcein AM for a further hour to label and detach migrated cells.  
Fluorescence in the bottom wells was read at Ex/Em: 485/520 nm.  
 
2.6. Statistical analysis 
Data are expressed as mean ± standard deviation (SD) and analysed using Mann-
Whitney U test. A p value of less than 0.05 was considered statistically significant. For 
all data, n represents the number of wells or dishes tested under each condition and 
also the results from at least two primary cell populations.  
 
3. Results 
3.1. CathL induces proliferation of HOMECs 
The tumour microenvironment is rich in tumour-secreted factors that activate normally 
relatively quiescent ECs, inducing angiogenesis which ensures a nutrient supply for 
the growing tumour. Cellular proliferation and migration are two key elements of this 
proangiogenic process. We have previously reported that CathL is secreted by EOC 
cells and since CathL has been reported to be involved in angiogenesis [20], initial 
studies examined the dose dependent (20, 50 and 80 ng/ml) proliferative effects of 
CathL on HOMECs. The concentration range was selected based on previously 
published concentrations of CathL concentration in the serum of ovarian cancer 
patients [14] and in the serum of patients with rheumatoid arthritis [21]. 50 ng/ml CathL 
induced a significant increase in HOMEC proliferation after 72 hours (147.0±25.8% vs 
control, [100%], p=<0.001; Fig. 1a), and thus this concentration was used for all further 
experiments. 
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CathL-induced (50 ng/ml) HOMEC proliferation was further confirmed using two 
separate methods: BrdU and CyQUANT, which demonstrated a significant increase in 
cellular proliferation. For instance, in response to CathL treatment, HOMEC 
proliferation significantly increased to 133.5±10.4% (p<0.05; Fig. 1b) and 109.1±5.0% 
(p<0.01; Fig. 1c) in BrdU and CyQUANT assays respectively, where all were 
normalised to control (100%). 
 
3.2. CathL induces HOMEC proliferation via a non-proteolytic mechanism 
Next, a series of experiments were performed to investigate whether mature CathL 
enhances HOMEC proliferation in a manner that is dependent on its proteolytic activity. 
Previously, CathL has been shown to be proteolytically active at neutral pH [22]. Thus, 
initial studies examined whether CathL was proteolytically active in the cell culture 
conditions studied. Preliminary studies confirmed that the pH of cell growth media in 
both the presence and absence of CathL remained at between pH 7.11 and 7.19 even 
over 72 hours of cell culture (Table 2). Using a fluorogenic substrate ZVA (5 µmol/l) 
CathL enzymatic activity was then tested over a range of pHs from 3 to 7.6 (data not 
shown) which included the published optimum pH for proteolytic activity (pH 5.5) and 
the pH neutral conditions confirmed above in cell culture (pH 7-7.6). CathL activity 
peaked at pH 5 and remained significant, though at a lower level, even at pH 7 (Fig. 
2a), confirming previously published work suggesting CathL proteolytic activity at both 
optimum and neutral pHs [22]. When co-incubated with FY-CHO (10 μmol/l), a well-
known inhibitor of CathL-proteolytic activity, CathL-mediated cleavage of the substrate 
was completely inhibited at pH 5 and 7 confirming the effectiveness of the inhibitor 
(Fig. 2a) 
 
Fig. 2b demonstrates that CathL-induced proliferation of HOMECs was not inhibited 
by FY-CHO over a range of concentrations including 10 μmol/l which fully inhibited the 
enzymatic activity of CathL above (Fig. 2a). The data presented in Fig. 2c confirm that 
FY-CHO had no effect on HOMECs proliferation at any of the concentrations used i.e. 
between 0.1 μmol/l and 10 μmol/l.  
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These combined data indicate that CathL is not proteolytically active in the assay 
conditions studied (i.e. neutral pH in the presence of FY-CHO) and that therefore the 
proliferative effect of CathL in HOMECs is not likely to be the result of its proteolytic 
activity but rather via a non-proteolytic mitogenic mechanism.  
 
3.3. CathL activates the proliferative kinases ERK1/2 and AKT (S473) 
 
The observation that CathL exerts its mitogenic effects in HOMECs via a non-
proteolytic mechanism raises the possibility that the protein acts as an extracellular 
ligand, interacting with an, as yet unknown, receptor to activate intracellular signalling 
pathways. This was initially investigated using a proteome-profiler phosphokinase 
array as a screening tool. Several kinases were identified to be phosphorylated in 
HOMECs during CathL treatment for 4 minutes. These included the known cell 
proliferative kinases ERK1/2 and AKT which demonstrated a 3-fold increase in 
phosphorylation, during CathL treatment compared to control (Fig. 3a).  
 
To confirm this initial screen, a cell-based ELISA was carried out following 4 and 10 
minutes incubation with CathL and VEGF165, where VEGF165 was the positive control. 
After 4 minutes treatment with CathL, there was a >2-fold and ~1.6-fold increase in 
ERK1/2 and AKT phosphorylation relative to the total ERK1/2 and AKT levels 
respectively and compared to control (untreated) (Fig. 3b, d). However, after 10 
minutes incubation, phosphorylated levels of both ERK1/2 and AKT reduced to the 
basal level observed in untreated cells (Fig. 3c, e). Interestingly, although CathL-
induced ERK1/2 phosphorylation was transient, VEGF165-induced ERK1/2 
phosphorylation was maintained for at least 10 minutes.  
 
The validity of the cell-based ELISA kit was verified using known inhibitors of MEK1/2 
and PI3K/AKT. Pre-incubation with non-toxic concentrations (determined during 
preliminary investigations, data not shown) of MEK1/2 inhibitors U0126 (10 μmol/l) 
and PD98059 (25 μmol/l) totally abolished the CathL (and VEGF165) induced increase 
in phosphorylation (Fig. 4a, b). Similar results were observed in the AKT ELISA using 
LY294002, a PI3K inhibitor and MK2206, a selective AKT inhibitor (Fig. 4c, d). These 
data confirm that both drugs inhibit the PI3K/AKT pathway in HOMECs. 
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3.4. CathL-induced HOMEC proliferation is mediated via ERK1/2 pathway, and 
not AKT 
 
The data presented above suggest that CathL-induced HOMEC proliferation involves 
the activation of ERK1/2 and AKT. This is confirmed by the data shown in Figure 5 
showing that both MEK1/2 inhibitors, U0126 and PD98059, significantly reduced 
CathL-stimulated proliferation to levels equal to or below control levels. For example, 
in the presence of 10 µmol/l U0126, cell proliferation decreased to 88.2±11.4% (vs 
CathL 134.8±14.7%, p<0.001, Fig. 5a), all normalised to control. In the case of 
PD98059, cell proliferation was reduced to 64.4± 4.9% (Fig. 5b) at 25 μmol/l, 
compared to CathL alone (127.0±7.9%, p<0.001) (all expressed as percentage of 
control). A similar observation was made in HOMECs treated with CathL in the 
presence of the PI3K inhibitor LY294002 (102.0±5.9% vs 137.3±5.7% CathL-only 
treatment, p<0.001, both normalised to control, Fig. 5c). However, cell proliferation 
was not significantly altered in the presence of MK2206, a selective inhibitor of AKT 
(discussed later). For example, cell proliferation in the presence of CathL plus 5 μmol/l 
of MK2206 was 126.7±10.9% (Fig. 5d) compared with CathL-induced proliferation, 
125.1±6.7% (all data normalised to control (100%)). Together, these data suggest that 
CathL induces HOMEC proliferation via a non-proteolytic mechanism that involves 
activation of intracellular pathways downstream of ERK1/2 phosphorylation and 
possibly PI3K. 
 
3.5. HOMEC migration is induced by CathL treatment via the ERK1/2, but not the 
AKT pathway 
 
Endothelial cell migration is another key step in tumour-angiogenesis. In an initial 
experiment, CathL significantly increased HOMEC migration by 197.4±49.6% 
(p>0.001; data not shown) compared to control (100%). This prompted an 
investigation into the downstream signalling cascades. Inhibitors of MEK1/2 
completely abolished CathL-induced HOMEC migration to basal levels observed in 
control, untreated wells. For instance, in the presence of U0126 and PD98059, CathL-
induced HOMEC migration reduced to 75.6±19.1% (Fig. 6a) and 91.5±14.1% (Fig. 6b) 
respectively, compared to CathL treatment alone (146.6±17.3%, p<0.001), all 
expressed as percentage of control (100%). In the case of PI3K/AKT inhibitors 
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LY294002 and MK2206, no significant reduction in CathL-induced HOMEC migration 
was observed. For instance, in the presence of LY294002 and MK2206, CathL-
induced cell migration was 188.8±46.5% (Fig. 6c) and 175.3±27.0% (Fig. 6d.) 
respectively, compared to CathL treatment (199.2±62.2%, p<0.001), all expressed as 
percentage of control (100%). These data combined with the ELISA data (Fig. 4), 
suggest that CathL induces HOMEC migration via a pathway that requires activation 
of the ERK1/2 but not the AKT(S473) pathway. 
 
4. Discussion 
 
The high mortality rate of ovarian cancer sufferers can be explained by late diagnosis 
at an advanced disease state, with widespread metastasis within the peritoneal cavity. 
This is primarily due to vague symptoms at an early stage of the disease, and hence 
diagnosis can be clinically challenging. Anti-angiogenic therapies that target the newly 
forming vasculature of the growing secondary foci have primarily targeted the 
VEGF/VEGFR2 axis and have had disappointing outcomes. This may be due to the 
compensatory contribution of other pro-angiogenic factors. Indeed, we have 
previously reported that omental angiogenesis in EOC metastasis could occur 
independently of VEGF165 signalling, potentially through alternative pro-angiogenic 
factors including CathL.  In vitro CathL is secreted from ovarian tumour cells and in 
vivo the overexpression of CathL is observed in omental tissue of patients with serous 
ovarian carcinoma [9, 15]. Additionally, CathL induced pro-angiogenic phenotypic 
changes in HOMECs [9], although the full effect of CathL and the mechanisms by 
which it acts to induce these cellular changes remain unknown. In this study, we 
demonstrate for the first time that CathL induces significant proliferation and migration 
via a mechanism that is not dependent on the proteolytic activity of the enzyme. 
Further to this, we also demonstrate that CathL induction of proliferation and migration 
was mediated via activation of the ERK1/2 pathway. These data support the 
hypothesis that CathL secreted from EOC metastasising to the omentum contributes 
to angiogenesis in the growing secondary tumour foci within the omentum. 
 
CathL is a lysosomal ubiquitous cysteine proteinase that plays an important role in 
degrading endocytosed proteins as well as intracellular proteins [11, 12]. CathL is 
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translated as preprocathepsin L (ppCathL) and processed into procathepsin L 
(pCathL) in the rough endoplasmic reticulum with a molecular mass of 30kDa and a 
two-chain form with molecular masses 25kDa and 5kDa [23, 24]. It is then transported 
to endosome/lysosomes via the mannose-6-phosphate/receptor (M6P/M6PR) 
pathway [25]. CathL contains covalently N-linked oligosaccharides including a 
mannose moiety that is phosphorylated by phosphodiesterases in the cis Golgi [26]. 
These M6P groups are recognised by an M6PR protein in the trans Golgi network 
(TGN), and facilitate the delivery of the protein to lysosomes (via endosomes) [27]. 
The cathepsins dissociate from the receptors at low lysosomal pH, and the phosphate 
group is removed from the M6P moiety by a lysosomal acid phosphatase [28]. 
However, CathL has also been shown to be secreted out of the cell. CathL was first 
identified as a major secreted protein from a transformed murine fibroblast cell line 
[29]. However, the mechanism of secretion of CathL remains a mystery. It has been 
shown that CathL has only one M6P residue, and hence it’s lower affinity for M6PR, 
as opposed to enzymes with two M6P residues such as cathepsin D [30-32].  
 
A role for extracellular CathL has been linked to tumour invasion and metastasis, 
particularly by degrading several ECM components such as proteoglycan, aggrecan, 
elastin, laminin, fibronectin and collagens: I, II, IX, XI [33-38]. Additionally, CathL has 
been shown to have a role in cell proliferation. A role for extracellular CathL in 
metastasis is less well studied, but our observation that CathL is secreted from EOC 
cancer cells led us to investigate its potential role in inducing a pro-angiogenic 
phenotype i.e. proliferation and migration, in disease-relevant HOMECS. We showed 
that CathL significantly stimulated proliferation in HOMECs within the reported 
physiological concentration range. We next examined whether CathL acts via a 
proteolytic- or non-proteolytic mechanism to induce this proliferation.  
   
 
Initial studies using ZVA, a CathL-specific fluorogenic substrate showed that CathL 
was proteolytically active across the pH range starting from its optimum pH (4.5) up to 
pH 7.6; which included the pH of cell culture media throughout a typical proliferation 
experiment (demonstrated to be between 7.11 and 7.19). These data are supported 
by  previous findings [39], demonstrating CathL  proteolytic activity at pHs between 7 
and  pH 8 and suggested that CathL is catalytically active in our cell  culture conditions. 
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We then examined whether FY-CHO, a selective, potent and non-cell permeable 
inhibitor of CathL catalytic activity, could inhibit CathL-induced proliferation in 
HOMECS. FY-CHO has previously been shown to be highly active against 
extracellular CathL. For instance, it has been extensively used to inhibit CathL 
mediated in vitro migration and invasion of breast and prostate cancer cells [40]. Here, 
this inhibitor was primarily chosen over cystatin C, a commonly used CathL inhibitor, 
because cystatin C elicits non-selective inhibition on all cysteine proteases.  
 
Preliminary studies, using ZVA, confirmed that FY-CHO completely inhibited CathL 
proteolytic activity at pH 7, however the same concentration (10 μmol/l), of FY-CHO 
had no effect on CathL-induced HOMEC proliferation, suggesting that CathL induces 
proliferation in these cells via a novel proteolytic-independent mechanism i.e. acts as 
an extracellular ligand. 
 
This led us to investigate the possible intracellular pathways activated by CathL in 
HOMECs. To address this, we investigated activation of possible downstream 
proliferative kinases in these cells using a human proteome profiler that identifies the 
phosphorylation status of 43 intracellular kinases. Both ERK1/2 and AKT 
phosphorylation levels were upregulated in HOMECs following CathL treatment, 
compared to control and these array data were confirmed using live cell-based 
ELISAs. Involvement of these kinases in mediating cellular proliferation was confirmed 
using well-known MEK1/2 (upstream of ERK1/2) inhibitors (U0126 and PD98059) and 
PI3K/AKT kinase inhibitors (LY294002 and MK2206). Initial ELISA experiments 
confirmed that these inhibitors fully abolished CathL-induced cellular ERK1/2 and AKT 
phosphorylation. In the subsequent experiments, we showed that the two MEK1/2 
inhibitors significantly reduced or abolished CathL-induced HOMEC proliferation over 
72 h. This observation was replicated in in the presence of LY294002 (PI3K inhibitor) 
but not with the selective AKT inhibitor MK2206. This is perhaps not surprising as 
LY294002 is known to cross-react with the ERK1/2 pathway where it inhibits ERK1/2 
phosphorylation [41]. Thus, it is possible that LY294002 in fact inhibited activation of 
ERK1/2 and reduced HOMEC proliferation, and that AKT is not involved in the 
induction of cell proliferation as the AKT-specific inhibitor failed to reduce this 
proangiogenic response. Taken together, these data suggest that the ERK1/2 
pathway is involved in the induction of HOMEC proliferation by exogenous CathL. 
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The observation that CathL induces intracellular activation of the MAPK ERK1/2 and 
PI3K/AKT pathways suggests the involvement of a cell surface receptor that initiates 
intracellular signalling following interaction with CathL. To date no CathL-activated 
receptors have been identified in ECs.  However, ECs do express a number of 
receptors that are known to be upstream of both signalling pathways e.g. VEGFR2 
and the epidermal growth factor receptor, and investigating possible receptor targets 
is a current focus of our research. 
 
We also showed that CathL induced migration in HOMECs, a second key pro-
angiogenic endothelial response. Investigation of the signalling pathways involved in 
the migratory response showed that CathL-induced HOMEC migration was only 
mediated via activation of the ERK1/2, but not the PI3K/AKT pathway. This is, to our 
knowledge, is the first report to observe such phenomenon.  
 
Taken together our data suggest that CathL may be an important pro-angiogenic factor 
in omental metastasis of EOC.  It is secreted from EOC and induces pro-angiogenic 
phenotypic changes in the local omental microvasculature. These observations are 
consistent with reports showing an increased level of secreted CathL in the sera of 
malignant epithelial ovarian cancer patients [14, 42], which correlated with a significant 
increase in the expression of CathL mRNA levels in tumours. Both serum levels and 
mRNA expression were higher in patients with malignant EOC than those with benign 
tumours or normal ovarian tissue. CathL has also been shown to be involved in the 
invasion and metastasis of EOC, and hence has been suggested to be a marker of 
advanced staged ovarian cancer [14]. This was supported by our published work 
demonstrating that the endothelium of vessels within omentum hosting metastatic 
ovarian high-grade serous carcinoma expressed significantly increased CathL in vivo 
compared with omentum from control patients with benign ovarian cystadenoma [15]. 
In other cancer types over-expression of CathL was linked to metastasis following ras 
transformation of NIH/3T3 cells in vitro [43] and  non-metastatic melanoma cells were 
converted to a metastatic state when over-expressing CathL in vitro [44]. It was also 
shown that CathL is involved in B16F10 melanoma cell invasion (in vitro), particularly 
through cell migratory influences [45]. It is known that CathL is secreted in different 
forms into the extracellular space in both physiological and pathological conditions and 
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retains its function as a protease which degrades ECM, which may allow cancer cells 
to invade surrounding tissue. 
 
A role for CathL in angiogenesis is a relatively new observation and, interestingly, 
evidence from different models suggests that CathL may be both pro-and anti-
angiogenic. For instance, recently, CathL derived from skeletal muscle cells 
transfected with bFGF was shown to promote migration of human umbilical vein ECs 
(HUVECs) in vitro [46]. Cell migration, a key component of angiogenesis, was tested 
in the presence of a cell impermeable CathL-proteolytic inhibitor FY-CHO and CathL 
for 12 hours. The data revealed a significant reduction in HUVEC migration, 
suggesting that CathL influences cell migration via its proteolytic-dependent 
mechanism. Subsequently, CathL was found to activate c-Jun N-terminal kinase (JNK) 
in migratory HUVECs. However, the exact role of CathL in activating the JNK pathway 
has not been elucidated [46]. Intriguingly, endothelial progenitor cells (EPCs) have 
been reported to produce CathL which in turn induced angiogenesis. Urbich et al. 
showed that EPCs were able to stimulate neovascularisation and blood flow in the 
ischaemic murine hind leg after injection into the affected leg [47]. Mature CathL was 
shown to remain proteolytically active extracellularly at neutral pH by the chaperone 
action of a p41 splice variant of the MHC class II-associated invariant chain [22], which 
indeed is strongly expressed in EPCs [47]. Such activity may facilitate EPC invasion 
and neovascularisation. Furthermore, mice treated with CathL-deficient bone marrow 
cells demonstrated a significant reduction in angiogenesis [47]. Another study also 
showed that CathL expressed in EPCs cells plays a critical role in intraocular 
angiogenesis [48]. In contrast, CathL was also shown to be antiangiogenic. For 
instance, both secreted and intracellular CathL have been shown to release 
endostatin, a potent inhibitor of angiogenesis, by cleaving ECM collagen [49]. Since 
the tumour microenvironment provides a slightly acidic milieu, CathL can efficiently 
cleave collagen even outside the cells. However, in other studies, CathL had no effect 
on angiogenesis. For example, Gocheva et al. demonstrated that CathL had no 
significant effects in altering microvascular density in pancreatic cancer in mice [50].  
Conclusion 
Taken together, the data presented here suggest that ovarian tumour-secreted CathL 
is a pro-angiogenic factor that induces proliferation and migration in HOMECs via a 
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non-proteolytic mechanism. These novel findings may contribute to the 
clinicopathology of advanced stage ovarian carcinoma where metastatic ovarian 
cancer causes extensive vascularisation of omental lesions, increasing the ability of 
the secondary tumour to survive and spread to other organs. As transcoelomic 
metastasis requires tumour angiogenesis, CathL, secreted from ovarian cancer cells, 
in cooperation with other cells present in the omentum may facilitate cellular 
angiogenesis in HOMECs. This may highlight CathL and its downstream pathways as 
novel anti-tumourigenic/anti-angiogenic therapeutic targets in the treatment of ovarian 
cancer. 
 
Abbreviations 
EOC, epithelial ovarian cancer; CathL, cathepsin L; EC, endothelial cell; ERK1/2, 
extracellular signal regulated kinase; AKT, protein kinase B; ECM, extracellular matrix.  
Competing interests 
The authors declare that they have no competing interests. 
Funding 
This project was funded by FORCE Cancer Charity, Devon (Grant 50703, Charity 
registration no. 1140676). 
Authors’ contributions  
MZIP performed experiments, collected results, did the data analysis and drafted the 
manuscript, NJG, MH and JLW supervised all the work and revised the manuscript. 
Consent for publication  
All the authors have read and approved the manuscript. 
Acknowledgements  
We would like to thank Boleslaw Winiarski for his help with HOMEC isolation and cell 
culture. This project was supported by the NIHR Exeter Clinical Research Facility. 
Disclosure 
Part of this article, in particular the methodology, has previously been published in 
“Cathepsin D non-proteolytically induces proliferation and migration in human omental 
18 
 
microvascular endothelial cells via activation of the ERK1/2 and PI3K/AKT pathways, 
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, Volume 1865, Issue 
1, January 2018, Pages 25-33.” 
 
Table 1. Concentrations of treatments added to cell proliferation assay. 
Treatments Purpose Concentration(s) Source 
Recombinant 
VEGF165 
Positive 
control  
20 ng/ml Peprotech (London, UK) 
Recombinant 
CathL from 
human liver 
Treatment 20, 50, 80 ng/ml Sigma-Aldrich (Poole, 
UK) 
FY-CHO CathL inhibitor 0.1, 1 and 10 µmol/l Santa Cruz 
Biotechnology, Inc. 
(Heidelberg, Germany) 
U0126 MEK1//2 
inhibitor 
10 µmol/l Stratech (Suffolk, UK) 
PD98059 MEK1/2 
inhibitor 
25 µmol/l Stratech (Suffolk, UK) 
LY294002  PI3K inhibitor 25 µmol/l Stratech (Suffolk, UK) 
MK2206  AKT inhibitor 5 µmol/l Stratech (Suffolk, UK) 
 
Table 2: pH of cell culture media and supernatant during CathL treatment. Cells 
were seeded in 6 well plates and treated with or without CathL (50 ng/ml) for 24, 48 
and 72 hours. Media were collected and their pH was measured. n.d. denotes not 
determined. 
  pH  
 0h 24h 48h 72h 
Basal mv2 7.34 n.d.  n.d. n.d. 
Untreated n.d. 7.19 7.13 7.12 
CathL  n.d. 7.19 7.13 7.11 
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Fig. 1. CathL increases proliferation of HOMECs. Cells were seeded in 2% gelatin 
pre-coated 96 well plates at a density of 10,000 cells/well in starvation media 
containing 2% FCS. After overnight incubation, cells were treated with or without 
various concentrations of CathL and incubated for a) 72 hours. WST-1 kit was used to 
assess cellular proliferation based on absorbance using a PHERAstar BMG plate-
reader at 450 nm (n = 15-20). b) Cell proliferation was tested using 50 ng/ml of CathL 
(BrdU). A commercially available BrdU reagent was added to the wells for the last 24 
hour incubation and cellular proliferation was assessed (according to the 
manufacturer’s instructions) at 48 hours after treatment based on fluorescence 
intensity using a SpectraMax plate-reader at Ex/Em of 450/550 nm (n = 6). c) HOMEC 
proliferation was examined at 50 ng/ml of CathL (CyQUANT). A commercially 
available CyQUANT reagent was used to assess cell proliferation after 72 hour 
treatment based on fluorescence intensity using FLUOstar BMG plate-reader at 
Ex/Em: 485/530 nm (n = 20). Results are mean ± SD and shown as percentage of the 
control, *p<0.05, **p<0.01 and ***p<0.001 vs control (100%). n.s. denotes not 
significant. 
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Fig. 2: FY-CHO inhibits CathL proteolytic activity at pH 7, but does not inhibit 
CathL-induced HOMEC proliferation. a) CathL proteolytic activity is inhibited at both 
pHs 5 and 7. A specific fluorogenic substrate Z-Val-Val-Arg-AMC (Z-VVR-AMC, ZVA, 
5 μmol/l) was incubated ± CathL (50 ng/ml) and in the absence or presence of FY-
CHO (10 μmol/l) at both pH 4 and 7. Fluorescence signals were measured immediately 
using a SpectraMax plate reader at Ex/Em: 365/440. Control wells contained pH buffer 
and substrate and/or inhibitor. The data are represented as percentage of control. 
*p<0.05, ***p<0.001 vs control (substrate) (100%); #p<0.05, ###p<0.001 vs CathL + 
substrate (expressed as % of control), n = 3. b + c) FY-CHO does not inhibit CathL 
induced proliferation. Cells were seeded in 2% gelatin pre-coated 96 well plates at a 
density of 10,000 cells/well in starvation media containing 2% FCS. After overnight 
incubation, cells were treated with or without CathL (50 ng/ml) and incubated for 72 
hours ± increasing concentrations of FY-CHO as indicated- b). c) Cells were seeded 
as for (b) and treated with FY-CHO alone for 72 hours. WST-1 assay was used to 
assess cellular proliferation based on absorbance using a PHERAstar BMG plate-
reader at 450 nm. Control wells contained 0.1% DMSO (carrier only). Results are 
mean ± SD and shown as percentage of the control, ***p<0.001 vs control (100%); n 
= 8-16. n.s. denotes not significant. 
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Fig. 3. CathL induces activation of the intracellular kinases ERK1/2 and AKT in 
HOMECs. a) CathL induces phosphorylation of ERK1/2 and AKT(S473) in HOMECs 
as assessed by proteome profile screening. Phosphorylation status of 43 intracellular 
kinases was assessed in lysates from cells treated ± CathL for 4 minutes. The results 
of 1 minute exposure are expressed as mean dot density (arbitrary units). The relative 
expression of specific phosphorylated proteins was determined following 
quantification of scanned images. b-e) CathL induces phosphorylation of ERK1/2 and 
AKT in HOMECs as assessed by live-cell ELISAs. Cells were seeded in 2% gelatin 
pre-coated 96 well plates at a density of 10,000 cells/well in starvation media 
containing 2% FCS. After overnight incubation, cells were treated with or without 50 
ng/ml of CathL or 20 ng/ml of VEGF (positive control) and incubated for 4 or 10 
minutes. ERK1/2 (b, c) and AKT (d, e) phosphorylation was examined after 4 minutes 
(b, d) and 10 minutes (c, e) treatments. Commercially available cell-based ELISAs 
were used for the determination ERK1/2 and AKT(S473) phosphorylation level. The 
ELISA experiments were carried out on two cell batches. The data is represented by 
fold change in phosho-ERK1/2/AKT relative to total ERK1/2/AKT (compared to 
control). Results are mean ± SD, **p<0.01 vs control (dotted lines); n = 4-6. n.s. 
denotes not significant. 
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Fig. 4. ERK1/2 and AKT phosphorylation was inhibited by their corresponding 
inhibitors in intact HOMECs. After overnight starvation in media supplemented with 
2% FCS, cells were pre-incubated with the MEK1/2 inhibitors a) U0126 (10 μmol/l) 
and b) PD98059 (25 μmol/l) or PI3K/AKT inhibitors c) LY294002 (25 μmol/l) and d) 
MK2206 (5 μmol/l) for (a + b) 20-30 minutes or (c + d) 2.5 hours, and then co-treated 
± 50 ng/ml of CathL or 20ng/ml of VEGF for 4 minutes. Commercially available cell-
based ELISAs were used for determination of ERK1/2 (a and b) and AKT (c and d) 
phosphorylation levels. The data in all are represented as fold change in phosho-
protein relative to total protein (compared to control). Results are mean ± SD, *p<0.05, 
**p<0.01 vs control (1-fold), #p<0.05 vs VEGF/CathL (normalised to control), n = 4. 
The dotted lines represent basal level (control) of phosphorylation status in untreated 
HOMECs. 
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Fig. 5. CathL-induced HOMEC proliferation is mediated via activation of the 
ERK1/2 and PI3K pathways, but not AKT pathway. After overnight starvation in 
media supplemented with 2% FCS, cells were treated with or without CathL (50 ng/ml) 
± a) U0126 (10 μmol/l), b) PD98059 (25 μmol/l), c) LY294002 (25 μmol/l) and d) 
MK2206 (5 μmol/l) and incubated for 72 hours. WST-1 assay was used to assess 
cellular proliferation. Results are mean ± SD and shown as percentage of the control, 
n.s., **p<0.01, ***p<0.001 vs control (100%), ###p<0.001 vs CathL (normalised to 
control 100%), n = 7-15. n.s. denotes not significant. 
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Fig. 6. CathL induces HOMEC migration via activation of the ERK1/2 (a, b), but 
not the AKT pathway (b, c). Pre-treated (with corresponding kinase inhibitor) 
HOMECs were seeded in the upper transwell chamber and treated with or without 
CathL (50 ng/ml) ± a) U0126 (10 μmol/l) and b) PD98059 (25 μmol/l) or c) PI3K and 
d) AKT inhibitors LY294002 (25 μmol/l) and MK2206 (5 μmol/l), respectively in media 
containing 0.5% FCS. The lower well contained correspondent treatments. After 6 
hours, migrated cells were stained with calcein AM and fluorescence was quantified 
using a FLUOstar plate reader at Ex/Em: 485/520. Results are mean ± SD and shown 
as percentage of the control, *p<0.05, **p<0.01, ***p<0.001 vs control (100%), 
###p<0.001 vs CathL (normalised to control (100%)), n = 6-12. n.s. denotes not 
significant. 
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